The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Phenylketonuria Therapeutic Market Research Report 2024
Synopsis
Phenylketonuria (PKU) is an inborn error of metabolism that results in decreased metabolism of the amino acid phenylalanine. Untreated PKU can lead to intellectual disability, seizures, behavioral problems, and mental disorder. It may also result in a musty smell and lighter skin. Babies born to mothers who have poorly treated PKU may have heart problems, a small head, and low birth weight.
Global Phenylketonuria Therapeutic market is projected to reach US$ 1783.2 million in 2029, increasing from US$ 1000 million in 2022, with the CAGR of 8.6% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Phenylketonuria Therapeutic market research.
The phenylketonuria (PKU) therapeutic market is primarily driven by the increasing prevalence of PKU and the growing demand for effective treatments to manage this rare genetic disorder. PKU is characterized by the inability to metabolize the amino acid phenylalanine, leading to its accumulation in the body, which can cause severe neurological and cognitive impairments if left untreated. As awareness about PKU and newborn screening programs improve, more patients are being diagnosed early, increasing the need for therapeutic interventions. However, the market also faces challenges, including the complexity of managing PKU through dietary restrictions and adherence to low-phenylalanine diets. This can be particularly challenging for young children and adults, impacting their quality of life and nutritional intake. Moreover, the limited availability of novel and more effective treatments for PKU poses a hurdle in addressing the unmet medical needs of patients. Addressing these challenges requires continued research and development of innovative therapies, including enzyme replacement therapies, gene therapies, and pharmacological interventions, to improve PKU management and alleviate dietary burdens. Additionally, raising awareness about PKU and its consequences among healthcare professionals and the general public is essential to facilitate early diagnosis and access to appropriate therapeutic options, ultimately driving the growth of the phenylketonuria therapeutic market and improving patient outcomes.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Phenylketonuria Therapeutic market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Biomarin
Mead Johnson
Abbott
Nutricia
Dr. Schär
Vitaflo
Cambrooke
PKU Perspectives
Firstplay Dietary
Segment by Type
Medications
Supplements
Segment by Application
Household
Hospital
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Phenylketonuria Therapeutic report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Phenylketonuria (PKU) is an inborn error of metabolism that results in decreased metabolism of the amino acid phenylalanine. Untreated PKU can lead to intellectual disability, seizures, behavioral problems, and mental disorder. It may also result in a musty smell and lighter skin. Babies born to mothers who have poorly treated PKU may have heart problems, a small head, and low birth weight.
Global Phenylketonuria Therapeutic market is projected to reach US$ 1783.2 million in 2029, increasing from US$ 1000 million in 2022, with the CAGR of 8.6% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Phenylketonuria Therapeutic market research.
The phenylketonuria (PKU) therapeutic market is primarily driven by the increasing prevalence of PKU and the growing demand for effective treatments to manage this rare genetic disorder. PKU is characterized by the inability to metabolize the amino acid phenylalanine, leading to its accumulation in the body, which can cause severe neurological and cognitive impairments if left untreated. As awareness about PKU and newborn screening programs improve, more patients are being diagnosed early, increasing the need for therapeutic interventions. However, the market also faces challenges, including the complexity of managing PKU through dietary restrictions and adherence to low-phenylalanine diets. This can be particularly challenging for young children and adults, impacting their quality of life and nutritional intake. Moreover, the limited availability of novel and more effective treatments for PKU poses a hurdle in addressing the unmet medical needs of patients. Addressing these challenges requires continued research and development of innovative therapies, including enzyme replacement therapies, gene therapies, and pharmacological interventions, to improve PKU management and alleviate dietary burdens. Additionally, raising awareness about PKU and its consequences among healthcare professionals and the general public is essential to facilitate early diagnosis and access to appropriate therapeutic options, ultimately driving the growth of the phenylketonuria therapeutic market and improving patient outcomes.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Phenylketonuria Therapeutic market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Biomarin
Mead Johnson
Abbott
Nutricia
Dr. Schär
Vitaflo
Cambrooke
PKU Perspectives
Firstplay Dietary
Segment by Type
Medications
Supplements
Segment by Application
Household
Hospital
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Phenylketonuria Therapeutic report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Phenylketonuria Therapeutic Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Medications
1.2.3 Supplements
1.3 Market by Application
1.3.1 Global Phenylketonuria Therapeutic Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Household
1.3.3 Hospital
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Phenylketonuria Therapeutic Market Perspective (2018-2029)
2.2 Phenylketonuria Therapeutic Growth Trends by Region
2.2.1 Global Phenylketonuria Therapeutic Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Phenylketonuria Therapeutic Historic Market Size by Region (2018-2023)
2.2.3 Phenylketonuria Therapeutic Forecasted Market Size by Region (2024-2029)
2.3 Phenylketonuria Therapeutic Market Dynamics
2.3.1 Phenylketonuria Therapeutic Industry Trends
2.3.2 Phenylketonuria Therapeutic Market Drivers
2.3.3 Phenylketonuria Therapeutic Market Challenges
2.3.4 Phenylketonuria Therapeutic Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Phenylketonuria Therapeutic Players by Revenue
3.1.1 Global Top Phenylketonuria Therapeutic Players by Revenue (2018-2023)
3.1.2 Global Phenylketonuria Therapeutic Revenue Market Share by Players (2018-2023)
3.2 Global Phenylketonuria Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Phenylketonuria Therapeutic Revenue
3.4 Global Phenylketonuria Therapeutic Market Concentration Ratio
3.4.1 Global Phenylketonuria Therapeutic Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Phenylketonuria Therapeutic Revenue in 2022
3.5 Phenylketonuria Therapeutic Key Players Head office and Area Served
3.6 Key Players Phenylketonuria Therapeutic Product Solution and Service
3.7 Date of Enter into Phenylketonuria Therapeutic Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Phenylketonuria Therapeutic Breakdown Data by Type
4.1 Global Phenylketonuria Therapeutic Historic Market Size by Type (2018-2023)
4.2 Global Phenylketonuria Therapeutic Forecasted Market Size by Type (2024-2029)
5 Phenylketonuria Therapeutic Breakdown Data by Application
5.1 Global Phenylketonuria Therapeutic Historic Market Size by Application (2018-2023)
5.2 Global Phenylketonuria Therapeutic Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Phenylketonuria Therapeutic Market Size (2018-2029)
6.2 North America Phenylketonuria Therapeutic Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Phenylketonuria Therapeutic Market Size by Country (2018-2023)
6.4 North America Phenylketonuria Therapeutic Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Phenylketonuria Therapeutic Market Size (2018-2029)
7.2 Europe Phenylketonuria Therapeutic Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Phenylketonuria Therapeutic Market Size by Country (2018-2023)
7.4 Europe Phenylketonuria Therapeutic Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Phenylketonuria Therapeutic Market Size (2018-2029)
8.2 Asia-Pacific Phenylketonuria Therapeutic Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Phenylketonuria Therapeutic Market Size by Region (2018-2023)
8.4 Asia-Pacific Phenylketonuria Therapeutic Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Phenylketonuria Therapeutic Market Size (2018-2029)
9.2 Latin America Phenylketonuria Therapeutic Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Phenylketonuria Therapeutic Market Size by Country (2018-2023)
9.4 Latin America Phenylketonuria Therapeutic Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Phenylketonuria Therapeutic Market Size (2018-2029)
10.2 Middle East & Africa Phenylketonuria Therapeutic Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Phenylketonuria Therapeutic Market Size by Country (2018-2023)
10.4 Middle East & Africa Phenylketonuria Therapeutic Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Biomarin
11.1.1 Biomarin Company Detail
11.1.2 Biomarin Business Overview
11.1.3 Biomarin Phenylketonuria Therapeutic Introduction
11.1.4 Biomarin Revenue in Phenylketonuria Therapeutic Business (2018-2023)
11.1.5 Biomarin Recent Development
11.2 Mead Johnson
11.2.1 Mead Johnson Company Detail
11.2.2 Mead Johnson Business Overview
11.2.3 Mead Johnson Phenylketonuria Therapeutic Introduction
11.2.4 Mead Johnson Revenue in Phenylketonuria Therapeutic Business (2018-2023)
11.2.5 Mead Johnson Recent Development
11.3 Abbott
11.3.1 Abbott Company Detail
11.3.2 Abbott Business Overview
11.3.3 Abbott Phenylketonuria Therapeutic Introduction
11.3.4 Abbott Revenue in Phenylketonuria Therapeutic Business (2018-2023)
11.3.5 Abbott Recent Development
11.4 Nutricia
11.4.1 Nutricia Company Detail
11.4.2 Nutricia Business Overview
11.4.3 Nutricia Phenylketonuria Therapeutic Introduction
11.4.4 Nutricia Revenue in Phenylketonuria Therapeutic Business (2018-2023)
11.4.5 Nutricia Recent Development
11.5 Dr. Schär
11.5.1 Dr. Schär Company Detail
11.5.2 Dr. Schär Business Overview
11.5.3 Dr. Schär Phenylketonuria Therapeutic Introduction
11.5.4 Dr. Schär Revenue in Phenylketonuria Therapeutic Business (2018-2023)
11.5.5 Dr. Schär Recent Development
11.6 Vitaflo
11.6.1 Vitaflo Company Detail
11.6.2 Vitaflo Business Overview
11.6.3 Vitaflo Phenylketonuria Therapeutic Introduction
11.6.4 Vitaflo Revenue in Phenylketonuria Therapeutic Business (2018-2023)
11.6.5 Vitaflo Recent Development
11.7 Cambrooke
11.7.1 Cambrooke Company Detail
11.7.2 Cambrooke Business Overview
11.7.3 Cambrooke Phenylketonuria Therapeutic Introduction
11.7.4 Cambrooke Revenue in Phenylketonuria Therapeutic Business (2018-2023)
11.7.5 Cambrooke Recent Development
11.8 PKU Perspectives
11.8.1 PKU Perspectives Company Detail
11.8.2 PKU Perspectives Business Overview
11.8.3 PKU Perspectives Phenylketonuria Therapeutic Introduction
11.8.4 PKU Perspectives Revenue in Phenylketonuria Therapeutic Business (2018-2023)
11.8.5 PKU Perspectives Recent Development
11.9 Firstplay Dietary
11.9.1 Firstplay Dietary Company Detail
11.9.2 Firstplay Dietary Business Overview
11.9.3 Firstplay Dietary Phenylketonuria Therapeutic Introduction
11.9.4 Firstplay Dietary Revenue in Phenylketonuria Therapeutic Business (2018-2023)
11.9.5 Firstplay Dietary Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
